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Trophoblastic disease represents a spectrum of conditions ranging
from hydatidiform mole to choriocarcinoma. Persistent tropho-
blastic disease (PTD) may follow either a molar pregnancy
(complete or partial hydatidiform mole) or a non-molar event, for
example an ectopic or normal pregnancy. In the UK, all patients
diagnosed with a molar pregnancy are followed up with regular b
human chorionic gonadotrophin (hCG) urinalysis. In the majority
of patients the trophoblastic disease remits following one or more
uterine evacuations and there is no need for systemic therapy. In
those where trophoblastic disease persists, the criteria for
chemotherapy are as follows: an hCG greater than 20 000 iu/L
after one or two uterine evacuations; a static or rising hCG level
after one or two uterine evacuations; persistent uterine haemor-
rhage with a raised hCG level; pulmonary metastases with static or
rising hCG levels; metastases in liver, brain or gastrointestinal
tract; and a histological diagnosis of choriocarcinoma.
In this paper we report our experience using chemotherapy
regimens that have been formulated in Sheffield, are more conser-
vative than many equivalent therapies, appear well tolerated 
and are seemingly very effective. Intravenous (i.v.) methotrexate,
etoposide and dactinomycin (MEA) chemotherapy is administered
as first-line chemotherapy for patients with high risk disease and
in the form of etoposide and dactinomycin (EA) to those patients
requiring salvage chemotherapy following unsuccessful low dose
intramuscular (i.m.) methotrexate chemotherapy for low risk
disease. Toxicity, both acute and long-term, response to therapy
and overall survival have been evaluated.
PATIENTS AND METHODS
Sheffield is one of three supra-regional screening centres (and one
of two treatment centres) in the UK for the management of gesta-
tional trophoblastic disease. All patients are initially managed
locally by a gynaecologist and by uterine evacuation(s). Patients
with PTD are admitted to this unit for assessment; a history is
taken and a physical examination (including a pelvic examination)
performed. Serum bhCG level, chest X-ray, computerized tomo-
graphic (CT) scan of the chest and an ultrasound scan of the
abdomen and pelvis are evaluated and a risk score assigned using
the Sheffield modification of the Charing Cross system (Table 1)
(Bagshawe et al, 1976; Sheridan et al, 1993). Approximately 5%
of all patients registered received chemotherapy, with 80% being
deemed to have low risk disease and 20% high risk disease. The
patients continued on chemotherapy until 8 weeks after achieving
a biochemical complete response (CR), that is normal serum
bhCG levels.
A retrospective analysis of the case notes of all women treated
with chemotherapy since 1986 was carried out. All women 
who received first-line high risk chemotherapy with MEA and
those who initially received low risk chemotherapy with i.m.
Persistent gestational trophoblastic disease: results of
MEA (methotrexate, etoposide and dactinomycin) as
first-line chemotherapy in high risk disease and EA
(etoposide and dactinomycin) as second-line therapy for
low risk disease
LS Dobson, PC Lorigan, RE Coleman and BW Hancock
Gestational Trophoblastic Disease Centre, Weston Park Hospital, Sheffield, UK
Summary Persistent gestational trophoblastic disease is potentially fatal, but the majority of patients are cured with chemotherapy. Any
developments in treatment are therefore being directed towards maintaining efficacy and reducing toxicity. We evaluated efficacy and toxicity
of methotrexate, etoposide and dactinomycin (MEA) as first-line therapy for high risk disease and etoposide and dactinomycin (EA) as
second-line therapy for methotrexate-refractory low risk disease in a retrospective analysis of 73 patients (38 MEA, 35 EA) treated since 1986
at a supra-regional centre. The median follow-up period was 5.5 years and the median number of cycles received was 7. The overall complete
response rate was 85% (97% for EA, 75% for MEA). Of eight patients who failed to respond, four have since died and four were cured with
platinum-based chemotherapy. Alopecia was universal. Grade II or worse nausea, emesis, or stomatitis was observed in 29%, 30% and 37%
respectively. Fifty-one per cent experienced grade II/III anaemia, 8% grade II or higher thrombocytopenia and 64% grade III or IV neutropenia;
in six cases this was complicated by sepsis. Fifty-four per cent of patients went on to have a normal pregnancy. No patient has developed a
second malignancy. In conclusion, the MEA and EA chemotherapy regimens for persistent trophoblastic disease are very well tolerated, do
not appear to affect future fertility and are associated with excellent, sustained complete response rates. © 2000 Cancer Research Campaign
Keywords: gestational trophoblastic disease; combination chemotherapy
1547
Received 20 September 1999
Revised 14 January 2000
Accepted 25 January 2000
Correspondence to: BW Hancock, Yorkshire Cancer Research Section of
Clinical Oncology, Weston Park Hospital, Sheffield, UK
British Journal of Cancer (2000) 82(9), 1547–1552
© 2000 Cancer Research Campaign
DOI: 10.1054/ bjoc.2000.1176, available online at http://www.idealibrary.com on methotrexate who, because of toxicity or refractory disease, subse-
quently received second-line EA chemotherapy were identified.
The following information was collected: reason for
chemotherapy; number of treatment cycles received; response to
treatment; clinical, haematological and biochemical toxicity expe-
rienced (graded by the common toxicity criteria); and evidence of
fertility.
Patients with high risk disease (score ³ 8) received intravenous
MEA chemotherapy (Table 2) with i.v. dexamethasone and
granisetron, for anti-emesis. Patients with central nervous system
(CNS) involvement (either a cerebral metastasis on CT scan or a
cerebrospinal fluid to venous blood hCG ratio of greater than 1:60)
received intrathecal methotrexate (12.5 mg) and a higher dose of
i.v. methotrexate (1 g m–2). Patients with low risk disease (score ≤
7) received i.m. methotrexate, 50 mg on alternate days for four
doses with folinic acid rescue. There was a 7-day interval between
courses. Patients with unacceptable toxicity or disease refractory
to first-line therapy (that is static or rising serum bhCG) received
salvage therapy with EA chemotherapy (Table 2).
RESULTS
Patient characteristics
Between 1986 and 1997, 4677 patients were registered with gesta-
tional trophoblastic disease and 224 (4.8%) required treatment.
Seventy-seven patients received either MEA (40 patients) or EA
(37 patients). Complete data were available for 73 patients (38
received first-line MEA chemotherapy, and 35 patients second-
line EA chemotherapy). Their clinical features are summarized in
Table 3. A total of 194 patients were scored as having low risk
disease and received i.m. methotrexate with folinic acid rescue.
Thirty-five (18%) of these received second-line EA chemotherapy.
Three were converted to EA therapy as a result of unacceptable
methotrexate toxicity (two with abdominal pain, one with
pleurisy) and 32 patents (16.5%) had methotrexate refractory
disease. A median of six courses of low dose methotrexate (range
2–10 courses) was given prior to conversion to second-line
therapy. Thirty-two patients were evaluable to determine the
efficacy of EA chemotherapy in methotrexate-resistant disease
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Table 1 Charing Cross prognostic scoring system
Variable 0 1 2 6
Age (years) < 39 > 39
Antecedent pregnancy (AP) Mole Abortion or unknown Term
Interval from AP to treatment (months) < 4 4–6 7–12 > 12
bhCG (IU l–1)1 0 3–104 < 103 104–105 > 105
ABO blood group A ´ OB   ´ A or O
O ´ A AB ´ A or (female ´
O or A ´ O male)
unknown
Number of metastases Nil 1–4 4–8 > 8
Site of metastases Lungs, vagina Spleen, kidneys Gastrointestinal tract, Brain
liver
Largest tumour mass < 3 cm 3–5 cm > 5 cm
Previous chemotherapy Nil Single drug Two or more drugs
Table 2 The MEA and EA chemotherapy regimens
MEA chemotherapy
Methotrexate 300 mg m–2 i.v.
Folinic acid rescue, 15 mg 6-hourly to commence 24 h
after chemotherapy, eight doses, the first four being
given intravenously.
7-day break
Etoposide 100 mg m–3 day–1 i.v. for 3 days
Dactinomycin, 0.5 mg day–1 i.v. for 3 days.
7-day break and repeat from methotrexate
EA chemotherapy
Etoposide 100 mg m–2 day–1 i.v. for 3 days
Dactinomycin 0.5 mg day–1 i.v. for 3 days
7-day break and repeat
These schedules are continued for 8 weeks after complete remission (normal
bHCG levels).
Table 3 Clinical features of patients treated
MEA EA
chemotherapy chemotherapy
(38 patients) (35 patients)
Age (years) < 39 32 (84%) 32 (91%)
> 39 6 (16%) 3 (9%)
Antecedent Mole 21 (55%) 33 (94%)
pregnancy (AP) Term 12 (32%) 1 (3%)
Other 5 (13%) 1 (3%)
Time from AP < 4 24 (63%) 21 (60%)
(months) 4–6 7 (18%) 12 (34%)
7–12 3 (8%) 1 (3%)
> 12 4 (11%) 1 (3%)
Presence of liver
and/or brain 5 (13%) 0 (0%)
metastasesand 35 were evaluable for toxicity. All patients receiving first-line
MEA were evaluable for response and toxicity.
Response to treatment (Table 4)
A total of 744 cycles of treatment were prescribed, 487 MEA and
257 EA. The median number of cycles of both EA and MEA
received was seven (range 1.5–12 cycles). The CR rate for all
patients was 85%. In patients receiving second-line EA therapy for
methotrexate refractory low risk disease, the CR rate was 97%.
The one patient who failed EA chemotherapy is currently alive but
with active disease; histology at presentation was a complete mole
and on relapse was a classical choriocarcinoma.
The CR rate for patients receiving MEA as first-line therapy
was 75%. Two patients received intrathecal methotrexate and high
dose methotrexate (1 g m–2) for CNS disease, one also had a cere-
bral metastasis resected. The latter was one of eight patients with
refractory disease who required second line platinum-containing
treatment; of these four were cured. Thirty-four patients (89%)
treated initially with MEA are alive and disease-free. Four have
died as a result of their disease; all were over the age of 40, in three
cases the histology was not that of classical choriocarcinoma (two
had placental site trophoblastic tumours) and one patient had CNS
involvement.
The median number of years of follow-up was 5.5 years (range
10 months to 11.5 years).
Toxicity (Table 4)
Haematological
EA chemotherapy was associated with grade III/IV neutropenia in 20
patients (57%), affecting 41 courses (16% total number of courses).
In two patients the neutropenia was complicated by sepsis. Five
patients (14%) required i.v. antibiotics during their chemotherapy for
non-neutropenic episodes; in each patient only one course was
affected. Nine patients (26%) required oral antibiotics.
MEA chemotherapy caused grade III/IV neutropenia in 26
patients (68%), affecting 54 courses (11% of total number of
courses). In four patients this was complicated by sepsis. Five
patients (13%) required i.v. antibiotics, with 16 (42%) receiving
oral antibiotics during their chemotherapy.
Two patients (8%) receiving EA exhibited grade III anaemia
during treatment, only three courses were affected. Sixteen
patients (46%) exhibited grade II anaemia and 16 patients were
transfused a total of 50 units of blood. MEA was associated with
grade III anaemia in one patient (3%) and grade II in 18 (47%); 15
patients required a blood transfusion, receiving a total of 58 units.
One patients receiving EA exhibited grade IV thrombocy-
topenia after one course. The patient required 10 units of platelets.
One patient on MEA also exhibited grade IV thrombocytopenia as
a result of disseminated intravascular coagulopathy secondary to
infection.
Forty-two courses (5.8%) of treatment received by 13 patients
(seven MEA, six EA) were supported with granulocyte-colony
stimulating factor. In all 13 cases this was due to previous grade III
or IV neutropenia; four patients also exhibited documented sepsis,
and in eight patients treatment had been compromised by delay. In
one patient the neutropenia was not complicated by either infec-
tion or delay in subsequent treatment course. A treatment delay of
over 14 days was observed in three patients (two patients on EA),
and in each case this was a result of neutropenic sepsis.
Non-haematological toxicity
Nine patients (26%) receiving EA exhibited grade II or III nausea.
Grade III or IV vomiting was observed in three cases (8%). Twelve
patients (32%) on MEA had grade II or III nausea. Grade III
vomiting only was seen in one patient. All patients exhibited
temporary grade III alopecia.
Grade II or III stomatitis was experienced in 13 patients (37%)
on EA and 14 patients (36%) on MEA. This affected 20 courses
(9%) and 25 courses (6%) respectively. Eight patients (23%)
receiving EA and 16 (42%) receiving MEA experienced a skin
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Table 4 Effects of treatment
MEA chemotherapy EA chemotherapy
No. patients in each group 38 35
Complete response rate 75% 97%
No. patients alive and disease free 34 34
Toxicity
Nausea – grade II/III 32% 26%
Vomiting – grade II/III/IV 26% 28%
Stomatitis – grade II/III 37% 37%
Alopecia – grade III 100% 100%
Cough 26% 17%
Conjunctivitis – grade I/II 76% 20%
Anaemia – grade II/III 50% 51%
Thrombocytopenia 8% 9%
Neutropenic sepsis 10.5% 6%
Patients requiring G-CSF support 18% 17%
Patients requiring blood transfusion 39% 46%
Patients requiring treatment delay 3% 6%
Patients requiring i.v. antibiotics 13% 14%
Patients requiring oral antibiotics 42% 26%
Abnormal liver enzymes – grade II/III 24% 0%
Patients with a subsequent normal 48% 60%
pregnancyrash which was self-limiting at some stage during their treatment.
Six patients (17%) on EA and ten (26%) on MEA experienced a
cough. Formal pulmonary toxicity with spirometry was not
assessed. Seven patients (20%) receiving EA and 29 (76%)
receiving MEA exhibited grade I or II conjunctivitis.
Twenty-seven courses of therapy were modified (12 courses of
EA and 15 of MEA). Nine patients (24%) who received MEA
chemotherapy experienced grade II/III abnormalities in hepatic
transaminases. Methotrexate was omitted in three high risk
patients, with two receiving EA and one continuing with dactino-
mycin only. The latter patient was on a drug rehabilitation
programme and her hCG levels had returned to normal. No
patient in the EA group exhibited grade II or higher alteration in
hepatic transaminases. Impairment of renal function was not
observed.
Long-term effects
Thirty patients (55%) became pregnant after chemotherapy; this
included two ectopic pregnancies and one miscarriage. Eighteen
patients have not had a further pregnancy and no information is
available on their current fertility status. Fertility was not ascer-
tained in 12 patients as it was too soon after chemotherapy. Six
women had a hysterectomy and three were using regular contra-
ception. Three patients, two who had EA, were attempting to
become pregnant. There have been no documented cases of second
malignancy.
DISCUSSION
The criteria for initiating chemotherapy for PTD vary from centre
to centre. In the USA a standard recommendation is that if bhCG
levels increase or plateau over a period of 3 or more consecutive
weeks, immediate work-up and treatment for PTD are indicated
(Goldstein and Berkowitz, 1995). At the other end of the spectrum,
UK clinicians advocate a more expectant policy and in low risk
cases are prepared to observe patients for up to 6 months with
serial bhCG estimations. Five per cent of patients registered at this
centre receive chemotherapy (Doreen et al, 1993; Sheridan et al,
1993; Hancock et al, 1997) compared with 7–8% at Charing
Cross, UK (Newlands 1997) and up to 20% in the USA (Kennedy
et al, 1995).
The Charing Cross experience
Patients are scored using the Charing Cross System (Table 1) and
are classified as being low risk (0–5), intermediate risk (6–9) or
high risk (> 9). Patients with low risk disease receive i.m.
methotrexate with folinic acid rescue. Twenty-five per cent require
alternative chemotherapy, which is virtually always successful
(Bagshawe et al, 1989; Newlands et al, 1997). In our study popu-
lation, where low risk was defined by a score of 0–7, alternative
chemotherapy (in the form of EA) was required in 18% of these
patients; the complete response rate with EA was 97%.
High risk patients (score > 9) are treated with EMA/CO (etopo-
side [100 mg m–2 i.v. on days 1 and 2], methotrexate [300 mg m–2
i.v. on day 1, followed at 24 h by folinic acid 15 mg 12-hourly
hourly ´ 4], dactinomycin [0.5 mg i.v. on days 1 and 2]/cyclophos-
phamide [600 mg m–2 i.v. on day 8] vincristine [1.4 mg m–2 i.v. on
day 8]); in addition patients with pulmonary metastases are given
CNS prophylaxis with intrathecal methotrexate (Bower et al,
1997). Overall survival was 85% when EMA/CO it was given to
148 patients between 1979 and 1989 (Newlands et al, 1991). There
were two categories of treatment failure. In 76 patients who
received EMA/CO as first-line therapy, ten of the 14 cases
progressed on therapy having had extensive disease at diagnosis.
The overall response rate was 82%. This was similar to our overall
response rate of 80%, however it is worth noting that in our study,
patients received MEA with a risk score of 8 or higher, compared
with above 9 for EMA/CO at Charing Cross; CNS prophylaxis
was not given (Gillespie et al, 1999). In 72 patients who had
received prior chemotherapy either at Charing Cross or at another
hospital, the survival was better, with 64 patients being cured
(89%). In the eight patients who failed EMA/CO, the principal
cause of death was drug resistance. Salvage chemotherapy for high
risk patients consisted of cisplatin with etoposide alternating with
the EMA schedule and achieved an 82% response rate in this
setting (Newlands et al, 1991).
The American experience
In the USA, patients are usually staged using either the
International Federation of Gynaecology and Obstetrics (FIGO)
anatomical staging system (FIGO, 1992) or Hammond’s clinical
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Table 5 Comparison of the toxicity associated with EMA/CO and MEA/EA
No. of cycles (%)
Haematological EMA/CO MEA EA EMA/CO MEA EA
Grade III Grade III Grade III Grade IV Grade IV Grade IV
Neutropenia 21 8 11 12 3 5
Anaemia 4 0.2 1 1 0 0
Thrombocytopenia 2 0 0 1 0.2 0.3
Non-haematological EMA/CO MEA EA EMA/CO MEA EA
Grade 1 Grade I Grade I Grade II Grade II Grade II
Nausea 13 8 13 10 3 7
Stomatitis 8 8 6 7 4 7
Dermatitis 5 4 3 0.8 2 2
Pleuric pain 4 0 0 0 0 0
Diarrhoea 3 0 0 2 0 0
Conjunctivitis 18 4 2 0 2 0.4
Neuropathy 0.8 0 0 0.8 0 0classification for gestational trophoblastic disease (Hammond
et al, 1973). Whilst direct comparisons of these classifications with
the Charing Cross or WHO (World Health Organization) scoring
systems is not possible there is reasonable equivalence (Welsh
et al, 1999); thus similar groups of patients are selected for 
multiagent chemotherapy.
The New England Trophoblastic Disease Centre protocol for
management of FIGO stage I disease is based upon the desire to
preserve fertility. In patients who wish to preserve fertility, single-
agent chemotherapy is given with methotrexate or dactinomycin.
A complete remission was seen in 385 (93%) of 414 patients with
stage I disease (Berkowitz and Goldstein, 1997). This is higher
than response rates for first-line therapy in low risk disease
reported from the UK but probably reflects the fact that in general,
more patients are treated, 20% compared to 5–10%. It is possible
that this represents treatment of some patients that would other-
wise have been cured by curettage alone and in whom unnecessary
exposure to cytotoxic therapy could have been avoided. The
remaining 29 resistant patients (7%) later achieved remission with
either combination chemotherapy or surgical intervention. If a
patient no longer wishes to preserve fertility, hysterectomy (with
adjuvant single-agent chemotherapy) may be performed as
primary treatment. Patients with stage II and III disease are
assessed for prognostic factors using the WHO scoring system
(WHO, 1987). The prognostic factors are similar to those used in
the Charing Cross system but have a different weighting attached.
In general, low risk patients are treated with primary single-agent
chemotherapy and high risk patients are managed with primary
combination chemotherapy. A review of four reports shows 87%
remission rate with single-agent chemotherapy and an eventual
remission rate of 98.6% (DuBreschter et al, 1987; Dubuc-Lissor et
al, 1989; Ayhan et al, 1992; Soper et al, 1994a). Low risk patients
who fail first-line chemotherapy with methotrexate in the New
England Trophoblastic Center receive MAC (originally
methotrexate, 0.3 mg kg–1 i.m., dactinomycin 8–10 mg kg–1 i.v. and
chlorambucil 0.2 mg kg–1 orally or cyclophosphamide 250 mg i.v.:
each is given daily for 5 days and the cycle is repeated every 14 to
21 days) or EMA/CO chemotherapy. Similar to our experience, all
patients with methotrexate-resistant disease achieved a complete
response (Berkowitz and Goldstein, 1997). Management of stage
IV disease includes primary intensive chemotherapy with sequen-
tial methotrexate, dactinomycin and cyclophosphamide, and selec-
tive use of radiotherapy and surgery (Lurain, 1994). Using this
combination, approximately 80% of patients will achieve a
remission – similar to our experience with MEA.
Comparisons between the different chemotherapy
regimens
Unlike MEA and EMA/CO, MAC does not contain etoposide. The
dose of etoposide in EMA/CO is 66% of that in MEA (200 mg m–2
vs 300 mg m–2). Etoposide has been reported to be associated with
an increased risk of secondary tumours including leukaemia,
breast cancer, colon cancer and melanoma. At present, there have
been no reported second malignancies in our patients treated
with etoposide for gestational trophoblastic disease, but follow-up
is short and we have recently reduced the time period for
‘consolidation’ chemotherapy from 8 to 6 weeks.
There have been many studies reported on the use of combina-
tion chemotherapy in high risk disease and in patients failing
single-agent therapy (Hammond et al, 1973; Newlands et al, 1986;
Quinn et al, 1994; Soper et al, 1994b). In internationally reported
series MAC produced complete responses in 66% (113/170) of
patients when given as first line therapy (Lurain, 1994). Early
reports of therapy with EMA/CO were more encouraging with
93% (103/111) of patients responding completely to this regimen
as first-line and 78% (80/102) as second-line treatment (Lurain,
1994). MEA as first-line and EA as second-line therapy appear to
be equally effective – 85% and 97% respectively. However, as
emphasized previously, different centres use different criteria to
determine high risk disease so these results, though roughly
equivalent, may not be truly comparable.
Table 4 summarizes haematological and non-haematological
toxicity associated with EMA/CO (Newlands et al, 1991) and
MEA,EA. More courses of EMA/CO were associated with grade
III/IV anaemia, neutropenia and thrombocytopenia (5%, 33% and
3%) compared to MEA,EA (0.5%, 13%, 0.3%).
Grade I/II nausea was seen with both treatments (23%
EMA/CO, 15% MEA,EA). The incidence of stomatitis and
dermatitis were the same for both treatments; conjunctivitis was
more frequent with EMA/CO (18% compared with 5%) and no
patients receiving MEA or EA had problems with neuropathy,
diarrhoea or pleuritic chest pain.
MAC chemotherapy was associated with significant myelotoxi-
city after 2–3 treatment cycles. In approximately 6% this was life-
threatening and anaemia was a frequent complication (Hammond
et al, 1973).
In women treated with EMA/CO, Bower et al (1997) reported
the occurrence of second malignancies, most commonly acute
myeloid leukaemia, associated with etoposide administration. We
have as yet failed to demonstrate the occurrence of second malig-
nancies with MEA and EA, with a median follow-up of 5.5 years
(range 10 months to 11.5 years). This may be as a result of a
relatively short follow-up time and fewer patients assessed.
We conclude that the regimens (MEA, EA) which we have
consistently used since 1986 for high risk and methotrexate-resis-
tant PTD are as efficacious as, and possibly better tolerated than,
any other regimen reported to date for these two clinical situations.
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